| Patents for A61K 45 - Medicinal preparations containing active ingredients not provided for in groups (115,020) |
|---|
| 11/24/2005 | WO2004060303A3 Methods and reagents for the enhancement of virus transduction in the bladder epithelium |
| 11/24/2005 | US20050261584 Devices and methodologies useful in body aesthetics |
| 11/24/2005 | US20050261496 3-(Morpholin-4-ylsulfonyl)-5-(1,3-thiazol-2-yl)-1H-indole-2-carboxamide; inhibiting, modulating and/or regulating signal transduction of both receptor and non-receptor tyrosine kinases; anticarcinogenic, -diabetic, -arhtritic, -inflammatory agents; psoriasis; angiogenesisinhibitors; liver cirrhosis |
| 11/24/2005 | US20050261377 Methods of using rapid-onset selective serotonin reuptake inhibitors for treating sexual dysfunction |
| 11/24/2005 | US20050261369 Pharmaceutical composition comprising a beta-3-adrenoceptor agonist and a serotonin and/or norepinephrine reuptake inhibitor |
| 11/24/2005 | US20050261344 Treatment of lower urinary tract symptoms associated with overactive bladder in men and women |
| 11/24/2005 | US20050261338 Beta2-adrenergic receptor agonists |
| 11/24/2005 | US20050261335 Carvedilol formulations |
| 11/24/2005 | US20050261328 Pharmaceutical composition comprising beta-3-adrenoceptor-agonists and antimuscarinic agents |
| 11/24/2005 | US20050261323 Medical uses of novel carbamate-substituted pyrazolopyridine derivatives |
| 11/24/2005 | US20050261310 Piperazinylpiperidine derivatives as chemokine receptor antagonists |
| 11/24/2005 | US20050261305 Cyclic protein tyrosine kinase inhibitors |
| 11/24/2005 | US20050261283 Methods and compositions for the treatment of graft failure |
| 11/24/2005 | US20050261282 Treatment of basal ganglia-related movement disorders with 2,3-benzodiazepines |
| 11/24/2005 | US20050261267 Pharmaceutical formulation |
| 11/24/2005 | US20050261240 Carrageenan based antimicrobial compositions |
| 11/24/2005 | US20050261208 Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with an anti-IgE antibody for treatment of asthma or chronic obstructive pulmonary disease |
| 11/24/2005 | US20050261202 Sensitization to another anticancer therapy and/or amelioration of a side effect of another anitcancer therapy by treatment with a GST-activated anticancer compound |
| 11/24/2005 | US20050261187 Methods and compositions relating to MEK5 and cardiac hypertrophy and dilated cardiomyopathy |
| 11/24/2005 | US20050261182 Treatment of neurological dysfunction comprising fructopyranose sulfamates and erythropoietin |
| 11/24/2005 | US20050261165 compounds that inhibit activity of the AcrAB or AcrAB-like efflux pump are identified as compounds which reduce antibiotic resistance in a microbe that has 2 chromosomal mutations in a gene encoding an antibiotic target that renders it resistant and increased expression of at least one efflux pump |
| 11/24/2005 | US20050260767 Treatment with cytokines |
| 11/24/2005 | US20050260753 Cross-linked hyaluronic acid-laminin gels and use thereof in cell culture and medical implants |
| 11/24/2005 | US20050260732 Polypeptide crystal having a polyhistidine tag added to the C-terminal end; effectors; drug screening for enzyme inhibitors; multiple sclerosis, diabetes, Grave's disease, rheumatic arthritis, AIDS, cancer, immunomodulators |
| 11/24/2005 | US20050260708 Proteases and protease inhibitors |
| 11/24/2005 | US20050260644 Cell signaling proteins |
| 11/24/2005 | US20050260577 Detection of neurodegenerative disorders |
| 11/24/2005 | US20050260575 Method for identifying substances useful for treating inflammation using the response element to the ikbalpha ror receptor |
| 11/24/2005 | US20050260565 contacting in vitro a sample comprising chemokine 88C receptor with a putative ligand, detecting binding of the 88C receptor and the putative ligand; increase in 88C signal transduction activity indicates the ligand is an activator, a decreasein transduction activity indicates the ligand is an inhibitor |
| 11/24/2005 | US20050260555 Chemosensitivity measurement using caspase activity |
| 11/24/2005 | US20050260291 Methods and compositions for reactivating acetylcholinesterase |
| 11/24/2005 | US20050260288 Suppress cancer with complication by Canavalia ensiformis extract |
| 11/24/2005 | US20050260286 Intensive anti-cellulite formula |
| 11/24/2005 | US20050260285 Healthy prostate formula |
| 11/24/2005 | US20050260280 Contact lens and eye drop rewetter compositions and methods |
| 11/24/2005 | US20050260262 Comprising risedronate, a chelating agent, and, means for effecting delayed release of the risedronate and the chelating agent in the small intestine; enteric coating |
| 11/24/2005 | US20050260220 first component is the modified antigenic ectodomain of measles virus hemagglutinin protein, second component fused to first component that binds a surface protein of human immunodeficiency virus; for treating HIV infection and other therapeutic targets against which it is difficult to develop vaccines |
| 11/24/2005 | US20050260209 Ephrin-b receptor protein involved in carcinoma |
| 11/24/2005 | US20050260208 Binding agents and their use in targeting tumor cells |
| 11/24/2005 | US20050260192 Leukocyte function associated antigens comprising integrin I-domain for use in identifying modulators for prevention and treatment of inflammatory disorders; immunosuppressive agents |
| 11/24/2005 | US20050260181 Compositions and methods for tissue repair |
| 11/24/2005 | US20050260177 Compounds for immunotherapy and diagnosis of colon cancer and methods for their use |
| 11/24/2005 | US20050260174 Systems and methods for treating patients with processed lipoaspirate cells |
| 11/24/2005 | US20050260172 Culture of goblet cells |
| 11/24/2005 | US20050260139 Pharmaceutical compositions based on anticholinergics and CCR2 receptor antagonists |
| 11/24/2005 | DE102004019413A1 Use of substances (e.g. nucleic acids, proteins and peptides), which restrain/reduce the expression and/or activity of protein kinase C-epsilon for the treatment/prevention of e.g. circulatory and vascular diseases |
| 11/24/2005 | CA2567166A1 Medicaments containing n-sulfamoyl-n'-arylpiperazines for the prophylaxis or treatment of obesity and related conditions |
| 11/24/2005 | CA2566716A1 Prolongation of survival of an allograft by inhibiting complement activity |
| 11/24/2005 | CA2566326A1 Peritoneal dialysis solution |
| 11/24/2005 | CA2566190A1 Use of targeted oxidative therapeutic formulation in treatment of age-related macular degeneration |
| 11/24/2005 | CA2566188A1 Use of targeted oxidative therapeutic formulation in bone regeneration |
| 11/24/2005 | CA2566180A1 Use of targeted oxidative therapeutic formulation in treatment of cancer |
| 11/24/2005 | CA2565070A1 Anti-ctgf agents for the treatment of pancreatic cancer |
| 11/24/2005 | CA2563601A1 Combinations of substituted 1-phenyl-1,5-dihydro-pyrido- [3,2-b] indol-2-ones and other hiv inhibitors |
| 11/24/2005 | CA2563305A1 Combination therapies for cancer and proliferative angiopathies |
| 11/24/2005 | CA2563207A1 Use of selective cytokine inhibitory drugs in myelodysplastic syndromes |
| 11/24/2005 | CA2562715A1 Methods of using and compositions comprising immunomodulatory compounds for the treatment and management of myelodysplastic syndromes |
| 11/24/2005 | CA2561717A1 Combination of organic compounds |
| 11/24/2005 | CA2508065A1 Antiproliferative drug and delivery device |
| 11/23/2005 | EP1598065A2 Drugs for improving prognosis of brain injury |
| 11/23/2005 | EP1598054A2 Method of suppressing appetite |
| 11/23/2005 | EP1597257A1 Oxazole-derivatives as ppar agonists |
| 11/23/2005 | EP1597248A2 Sulfonamide derivatives as ppar modulators |
| 11/23/2005 | EP1597199A1 THERAPEUTIC MALONIC ACID/ACETIC ACID C sb 60 /sb TRI-ADDUCTS OF BUCKMINSTERFULLERENE AND METHODS RELATED THERETO |
| 11/23/2005 | EP1597171A2 Therapeutic microfoam |
| 11/23/2005 | EP1596884A2 Uses of integrin alphavbeta3 antagonists |
| 11/23/2005 | EP1596873A1 Combined use of ribavirin and interferon beta in demyelinating diseases |
| 11/23/2005 | EP1596872A1 Compositions and methods for restoring bacterial flora |
| 11/23/2005 | EP1596861A1 Pharmaceutical combinations comprising a nos inhibitor and an nmda receptor antagonist |
| 11/23/2005 | EP1596855A2 Methods and compositions for use in treating cancer |
| 11/23/2005 | EP1596854A2 Treatment of conditions associated with decreased nitric oxide bioavailability, including elevated arginase conditions |
| 11/23/2005 | EP1596847A1 New combination |
| 11/23/2005 | EP1596844A2 Use of sodium channel modulators for treating gastrointestinal tract disorders |
| 11/23/2005 | EP1596841A1 Therapeutic system comprising amoxicillin and clavulanic acid |
| 11/23/2005 | EP1596840A1 Use of p-glycoprotein inhibitor surfactants at the surface of a colloidal carrier |
| 11/23/2005 | EP1596821A2 Synergistic compositions and methods for potentiating anti-oxidative activity |
| 11/23/2005 | EP1596810A2 Treatment of inflammatory bowel disease |
| 11/23/2005 | EP1596808A2 L-dopa amide derivatives and uses thereof |
| 11/23/2005 | EP1596670A2 Oils enriched with diacylglycerols and phytosterol esters for use in the reduction of cholesterol and triglycerides |
| 11/23/2005 | EP1503754B1 Beta-agonist compounds comprising nitric oxide donor groups and reactive oxygen species scavenger groups and their use in the treatment of respiratory disorders |
| 11/23/2005 | EP1446015A4 Remodeling of tissues and organs |
| 11/23/2005 | EP1372645B1 Reconstitutable parenteral composition containing a cox-2 inhibitor |
| 11/23/2005 | EP1330226A4 Method for producing purified hematinic iron-saccharidic complex and product produced |
| 11/23/2005 | EP1328276B1 Use of antiprogestins for prophylaxis and treatment of hormone-dependent diseases |
| 11/23/2005 | EP1280777B1 Tetrahydroisoquinoline analogs useful as growth hormone secretagogues |
| 11/23/2005 | EP1267846B1 Transdermal therapeutic system for the delivery of lerisetron |
| 11/23/2005 | EP1258249B1 Oral preparations for diabetes |
| 11/23/2005 | EP1250124B1 Slimming cosmetic composition comprising as active agent a plant extract containing a plant natriuretic peptide (pnp) |
| 11/23/2005 | EP1200831B1 Modulating binding site on potassium channels used for screening |
| 11/23/2005 | EP1183034B1 Modulators of methylation for control of bacterial virulence |
| 11/23/2005 | EP1163528B1 Prediction of diabetes impaired wound healing |
| 11/23/2005 | EP1140291B1 Combination chemotherapy comprising a mitotic inhibitor and a mek inhibitor |
| 11/23/2005 | EP1140028B1 Biodegradable poly(phosphoester) compositions for treating ovarian cancer |
| 11/23/2005 | EP1137401B1 Administration of neurotrophic agents to the central nervous system |
| 11/23/2005 | EP1112106B1 Serotonergic 5ht2 agonists for treating glaucoma |
| 11/23/2005 | EP1104294B8 Compositions and methods of treating abnormal cell proliferation |
| 11/23/2005 | EP1023284B1 Anti-viral pharmaceutical compositions containing saturated 1,2-dithiaheterocyclic compounds |
| 11/23/2005 | EP0929311B1 INHIBITION OF APOPTOSIS USING INTERLEUKIN-1 beta-CONVERTING ENZYME (ICE)/CED-3 FAMILY INHIBITORS |
| 11/23/2005 | EP0906088B1 Liposomal antineoplaston therapies with markedly improved antineoplastic activity |
| 11/23/2005 | EP0869789B1 Antiviral agent |